MintNeuro Gains Investment to Advance Semiconductor Tech for Neural Implants

MintNeuro, a pioneer of scalable, low-power semiconductor technology for minimally invasive neural implant applications, has raised £1 million in a funding round led by Empirical Ventures. 

Developed at Imperial College London, MintNeuro uses semiconductor technology to make neural implants smaller, more efficient, and scalable. With over £14 million in underpinning R&D grant funding to date, the MintNeuro team leverages semiconductor manufacturing to allow cost-effective, mass-producible neural devices. 

Unlike conventional implants, the company’s compact, low-power chips enable modular designs adaptable to various neurological conditions, offering sensing, stimulation, and processing capabilities to enhance both functionality and accessibility.

“Millions of patients with neurological disorders face limited treatment options,” said Dorian Haci, CEO and co-founder of MintNeuro. “Our goal is to bridge that gap with safer, more accessible, and effective neural technology. This investment accelerates our chip development and enables us to expand our team of experts, bringing game-changing neural implants to clinicians for the benefit of patients everywhere.”

“Our semiconductor-based approach is fundamentally reshaping what neural implants can achieve,” said Timothy Constandinou, CTO and co-founder of MintNeuro. “By offering a customisable, compact solution that integrates seamlessly into medical devices, we’re empowering a new era of neural interfaces that are not only more powerful but also less invasive. This marks a transformative shift in neurological care.”

MintNeuro’s innovative semiconductor solutions have gained considerable traction through strategic partnerships with leading institutions and medical device companies. Collaborations include the NIHR-funded DREAM project with Imperial College London and King’s College London and Hospital, targeting the development of a breakthrough device for epilepsy monitoring, with a first-in-human study planned for next year. 

Also, MintNeuro’s has partnered with Amber Therapeutics, which has recently secured $100 million in funding. Amber Therapeutics is focused on developing a neuromodulation therapy chipset through an Innovate UK Smart grant. 

This technology initially targets mixed urinary incontinence, with the potential for future applications of the MintNeuro chipset in conditions such as Parkinson’s disease, dementia, and depression.

“MintNeuro is uniquely addressing the core limitations of neural implants with a semiconductor-based approach,” said Johnathan Matlock, General Partner at Empirical Ventures. “We are excited about the market opportunity and the potential of entrepreneurial scientists like Dorian and Tim to drive forward the next generation of neural implants.”

Additional investment came from Parkwalk Advisors (through the Imperial College Enterprise Fund), Imperial College London, Plug & Play, Excellis Holding, and several prominent angel investors.